November 02, 2017

Insys Executives Arrests Related to Sale of Fentanyl Spray

Subsys, is an opioid for cancer patients experiencing severe breakthrough pain. The DOJ has charged that executives at Insys, which produces Subsys, bribed physicians to prescribe Insys inappropriately for patients, executives gave kickbacks based on sales.  Most prescriptions written were for patients who were not diagnosed with cancer and did not qualify for treatment under the FDA guidelines for Subsys use.  Further, DOJ charged that Insys officials and employees engaged in a conspiracy to defraud insurance providers to assure payment for non-cancer treatment.